

**MEDX HOLDINGS, INC.**  
**A WYOMING CORPORATION**

**COMPANY INFORMATION AND DISCLOSURE STATEMENT**

**Pursuant to Pink Sheet Basic Disclosure Guidelines**

All information in this information and Disclosure Statement has been compiled to fulfill the disclosure requirement of the OTC Markets regarding Pink Sheet Basic Disclosure Guidelines.

No Dealer, salesman or any other person has been authorized to give any information, or to make any representations. Not contained herein in connection with the issuer. Such information or representations if made should not be relied upon as having been authorized by the issuer and;

Delivery of this information file does not at any time imply that the information contained herein is correct as of any time subsequent to the date first written

---

The undersigned hereby certifies that the information herein is true and correct to the best of their knowledge and belief.

Date: February 19, 2017

MedX Holdings, Inc.

/s/ Kathleen Robertson

Position: Director and CEO

Email: [kathy@medxholdings.com](mailto:kathy@medxholdings.com)

Phone: 877-337-3756

**MEDX HOLDINGS, INC.**  
**DISCLOSURE STATEMENT**

---

December 31, 2016

**Item 1: The exact name of the issuer and the address of its executive offices:**

The exact name of the issuer is: MedX Holdings, Inc.  
August 12, 2015 – Cantor Group  
November 13, 2006 – Disaboom, Inc.  
September 5, 2006 – Disaboo, Inc.

**Item 2: The Address of its principal executive offices:**

1621 Central Avenue  
Cheyenne, WY 82001

Phone: 877-225-0421  
Fax: 954-337-3756  
Website: [www.medxholdings.com](http://www.medxholdings.com)

**Item 3: Security Information**

Security Symbol: MEDH  
CUSIP Number: 58403T 107  
Common Stock: 27,425,000  
Par Value: \$0.001 on both Common and Preferred Shares

| As of:                      | 12/31/2015  | Par Value | 12/31/2016  | Par Value |
|-----------------------------|-------------|-----------|-------------|-----------|
| Total Authorized Common     | 100,000,000 | \$0.001   | 100,000,000 | \$0.001   |
| Total Authorized Preferred: |             |           |             |           |
| Series A Preferred          | 10,000,000  | \$0.001   | 10,000,000  | \$0.001   |
| Blank Check Preferred       |             |           |             |           |
| Shareholders                |             |           |             |           |

**Transfer Agent:**

Daniel Bell, Corporate Stock Transfer, Inc.  
3200 Cherry Creek Drive South  
Denver, Colorado 80209  
Phone: 303-282-4800

CST currently meets all requirement and is registered under the Securities Exchange Act.

Restriction on transfer of Securities or suspensions by the SEC in the past 12 months:

None

Stock Splits:

None

**Item 4: Issuance History:**

4/20/2016 – Enterprise Solutions Group: 1,100,000 shares of Common Stock, par value  
\$0.001

4/20/2016 – Enterprise Solutions Group: 1,125,000 Shares of Common Stock, par value  
\$0.001

**Item 5: Financial Statement**

- Balance Statement
- Profit and Loss Statement
- Statement of Cash Flows
- Financial Notes

# MEDX HOLDINGS, INC.

## BALANCE SHEET COMPARISON

As of December 31, 2016

|  | TOTAL               |                         |
|--|---------------------|-------------------------|
|  | AS OF DEC 31, 2016  | AS OF DEC 31, 2015 (PY) |
| <b>ASSETS</b>                          |                     |                         |
| Current Assets                         |                     |                         |
| Bank Accounts                          |                     |                         |
| BOA 8500                               | 101.62              |                         |
| BOA 9518                               | 0.00                |                         |
| Checking                               | 0.00                | 1,709.25                |
| <b>Total Bank Accounts</b>             | <b>\$101.62</b>     | <b>\$1,709.25</b>       |
| Other Current Assets                   |                     |                         |
| Note Receivable MEDX Pharmaceuticals   | 0.00                |                         |
| <b>Total Other Current Assets</b>      | <b>\$0.00</b>       | <b>\$0.00</b>           |
| <b>Total Current Assets</b>            | <b>\$101.62</b>     | <b>\$1,709.25</b>       |
| Other Assets                           |                     |                         |
| CAPITAL ASSETS                         | 146,000.00          | 146,000.00              |
| Capitalized Re-Organization Costs      | 13,000.00           | 13,000.00               |
| Intellectual Property                  | 200.00              |                         |
| <b>Total Other Assets</b>              | <b>\$159,200.00</b> | <b>\$159,000.00</b>     |
| <b>TOTAL ASSETS</b>                    | <b>\$159,301.62</b> | <b>\$160,709.25</b>     |
| <b>LIABILITIES AND EQUITY</b>          |                     |                         |
| Liabilities                            |                     |                         |
| Current Liabilities                    |                     |                         |
| Other Current Liabilities              |                     |                         |
| Accrued Interest                       | 0.00                |                         |
| Accrued Liabilities                    | 0.00                | 0.00                    |
| Accrued Salary                         | 135,000.00          |                         |
| Due to related party                   | 17,292.75           | 27,000.00               |
| <b>Total Other Current Liabilities</b> | <b>\$152,292.75</b> | <b>\$27,000.00</b>      |
| <b>Total Current Liabilities</b>       | <b>\$152,292.75</b> | <b>\$27,000.00</b>      |
| Long-Term Liabilities                  |                     |                         |
| Convertible Note Acquisition           | 6,500.00            |                         |
| Convertible Note Imperial              | 5,000.00            |                         |
| Convertible Note Uptick                | 6,000.00            |                         |
| <b>Total Long-Term Liabilities</b>     | <b>\$17,500.00</b>  | <b>\$0.00</b>           |
| <b>Total Liabilities</b>               | <b>\$169,792.75</b> | <b>\$27,000.00</b>      |
| Equity                                 |                     |                         |
| Common Stock                           | 4,221.00            | 4,221.00                |
| Opening Balance Equity                 | 0.00                |                         |
| Paid-In Capital or Surplus             | 722,739.00          | 717,239.00              |
| Preferred Stock Series "A"             | 175,000.00          |                         |
| Retained Earnings                      | -587,750.75         | -587,460.00             |
| Net Income                             | -324,700.38         | -290.75                 |
| <b>Total Equity</b>                    | <b>\$-10,491.13</b> | <b>\$133,709.25</b>     |

|                                     | TOTAL               |                         |
|-------------------------------------|---------------------|-------------------------|
|                                     | AS OF DEC 31, 2016  | AS OF DEC 31, 2015 (PY) |
| <b>TOTAL LIABILITIES AND EQUITY</b> | <b>\$159,301.62</b> | <b>\$160,709.25</b>     |

# MEDX HOLDINGS, INC.

## PROFIT AND LOSS COMPARISON

January - December 2016

|  | TOTAL                |                     |
|--|----------------------|---------------------|
|  | JAN - DEC 2016       | JAN - DEC 2015 (PY) |
| <b>INCOME</b>                          |                      |                     |
| <b>Total Income</b>                    |                      |                     |
| <b>EXPENSES</b>                        |                      |                     |
| Accounting Fees                        | 800.00               |                     |
| Bank Charges                           | 844.51               |                     |
| Consulting Fee                         | 16,199.67            | 0.00                |
| FINRA EXPENSE                          | 4,091.21             |                     |
| Interest Expense                       | 0.00                 |                     |
| LEGAL EXPENSE                          | 1,203.90             |                     |
| Meals And Entertainment                | 252.00               |                     |
| Office Expenses                        | 324.33               |                     |
| Office/General Administrative Expenses | 5,188.01             | 290.75              |
| OTC Fees                               | 4,325.00             |                     |
| Payroll Expenses                       |                      |                     |
| Salary Expense                         | 135,000.00           |                     |
| <b>Total Payroll Expenses</b>          | <b>135,000.00</b>    |                     |
| Press Release                          | 800.00               |                     |
| Rent or Lease of Buildings             | 8,930.00             |                     |
| Travel                                 | 517.36               |                     |
| Travel & Entertainment                 | 315.01               |                     |
| <b>Total Expenses</b>                  | <b>\$178,791.00</b>  | <b>\$290.75</b>     |
| <b>NET OPERATING INCOME</b>            | <b>\$-178,791.00</b> | <b>\$-290.75</b>    |
| <b>OTHER INCOME</b>                    |                      |                     |
| OTHER INCOME                           | -135,909.38          |                     |
| <b>Total Other Income</b>              | <b>\$-135,909.38</b> | <b>\$0.00</b>       |
| <b>OTHER EXPENSES</b>                  |                      |                     |
| Finder Fees                            | 10,000.00            |                     |
| <b>Total Other Expenses</b>            | <b>\$10,000.00</b>   | <b>\$0.00</b>       |
| <b>NET OTHER INCOME</b>                | <b>\$-145,909.38</b> | <b>\$0.00</b>       |
| <b>NET INCOME</b>                      | <b>\$-324,700.38</b> | <b>\$-290.75</b>    |



**MEDX HOLDINGS, INC**  
**( A Development Stage Company)**  
**Statement of Cash Flows**  
**January - December 2016 January - December 2015**

|  | January -<br>December 2016 | January -<br>December 2015 | Cumulative<br>results from<br>September 6<br>2006<br>(inception<br>date) to<br>December 31,<br>2016 |
|--|----------------------------|----------------------------|---|
| <b>OPERATING ACTIVITIES</b>  |                            |                            |   |
| Net Loss   | \$ (324,700)               | \$ (291)                   | (916,114)   |
| Adjustments to reconcile Net Income to Net<br>Cash provided by operations: |                            |                            |   |
| Intellectual Property (Logo)   | (200)                      |                            | (200)   |
| Accrued Liabilities  | 135,000                    | (16,000)                   | 134,663   |
| Due to related party   | (9,707)                    | 27,000                     | 29,293  |
| Net cash provided by operating activities                                  | (199,607)                  | 10,709                     | (752,158)   |
| <b>INVESTING ACTIVITIES</b>  |                            |                            |   |
| Capitalized Re-Organization Costs  |                            | (13,000)                   | (13,000)  |
| Purchase of Capital Asset  |                            |                            | (146,000)   |
| Net cash provided by investing activities                                  | -                          | (13,000)                   | (159,000)   |
| <b>FINANCING ACTIVITIES</b>  |                            |                            |   |
| Increase in Long Term Liabilities  |                            |                            |   |
| Convertible Notes  | 17,500                     |                            | 8,500   |
| Increase in Capital  |                            |                            |   |
| Common Stock   |                            | -                          | 4,221   |
| Paid-In Capital  | 5,500                      |                            | 717,239   |
| Preferred Stock Series "A"   | 175,000                    |                            | 175,000   |
| Paid In Surplus  |                            |                            |   |
| Retained Earnings  |                            | 4,000                      | 4,000   |
| Net cash provided by financing activities                                  | 198,000                    | 4,000                      | 908,960   |
| Net cash increase for period   | (1,607)                    | 1,709                      | 102   |
| Cash at beginning of period  | 1,709                      |                            | -   |
| Cash at end of period  | \$ 102                     | \$ 1,709                   | \$ 102  |

panying notes are an integral part of these financial statements.

**MEDX HOLDINGS, INC.**

**(A Development Stage Company)**

**NOTES TO THE UNAUDITED FINANCIAL STATEMENTS**

**December 31, 2016**

---

**NOTE 1 - SUMMARY OF OPERATIONS AND BASIS OF PRESENTATION**

MedX Holdings, Inc. formerly Cantor Group Inc. (the "Company") was incorporated in the State of Wyoming on December 23, 2015. The company has an established fiscal year end of December 31.

**NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES**

**Basis of Presentation**

The financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America and are presented in US dollars.

**Cash and Cash Equivalents**

The company considers all highly liquid instruments with a maturity of three months or less at the time of issuance to be cash equivalents.

**Use of Estimates and Assumptions**

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

**Financial Instruments**

The carrying value of the company's financial instruments approximates their fair value because of the short maturity of these instruments.

**Basic and Diluted Net Loss per Share**

The Company computes loss per share in accordance with "ASC-200". "Earnings per Share" which requires presentation of both basic and diluted earnings per share on the face of the statement of operations. Basic loss per share is computed by dividing net loss available to common shareholders by the weighted average number of outstanding common shares during the period. Dilutive loss per share gives effect to all dilutive potential common shares outstanding during the period. Dilutive loss per share excludes all potential common shares if their effect is anti-dilutive. The Company has outstanding three notes (CONVERTIBLE NOTES) which are potential dilutive instruments and accordingly, basic loss and diluted loss per share are presented.



In February of 2016 the company borrowed \$ 11,000 at 8% with conversion feature at 50% of bid of the previous 10 day average The potential dilutive effect of these instruments is 146,667 shares.

During the period from June to September of 2016 the company had eight investments of \$ 25,000.00 each. These investors each received 50,000 shares of series "A" Preferred Stock, par value \$ 0.001 with conversion of 1 to 1. The dilutive effect of these transaction is an additional 400,000 shares of common.

The Basic Common Stock authorized is 100,000,000 shares. As of 06/30/2016 the number of issued shares is 25,569,016 outstanding. The weighted average of fully diluted shares is 61,805,683.

### **NOTE 3 – GOING CONCERN**

The Company's financial statements are prepared using generally accepted accounting principles in the United States of America applicable to a going concern which contemplates the realization of assets and liquidation of liabilities in the normal course of business. The Company has restructured its board and its management team and has raised equity capital to position the company as a holding company focused on acquisition and development of businesses primarily in the medical products industry. The Company is utilizing a new form of collaborative governance to create added value.

The company attempted to enter the pharmaceutical distribution business with the creation of MEDX PHARMACEUTICALS, INC., a wholly owned subsidiary. As of December 31, 2016 MEDX HOLDINGS, INC. advanced \$ 135,909.38 as start up capital to begin operations. In November of 2016 the company closed MEDX PHARMACEUTICALS, INC. and elected to write off the entire amount as a loss.

The ability of the Company to continue as a going concern is dependent upon its continued ability to successfully accomplish the plans described in the preceding paragraphs. The accompanying financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

### **NOTE 4 - RELATED PARTY TRANSACTION**

As of March 31, 2016 the Company owed \$ 12,000.00 in a CONVERTIBLE NOTE with four (4) individuals each owning ¼ each of the note via a partial Note Assignment. In September of 2016 one individual lender forgave \$ 3000.00 of debt owed. The effect of this was to decrease convertible notes payable by \$ 3000.00 and to decrease the potential conversion by 12,000,000 shares of common. In December of 2016 one note holder converted \$625.00. Into common shares at 2,500,000 shares. The notes remain non-interest bearing. The notes convert at \$0.00025 up to 33,500,000 common shares.

On November 17, 2015, Small Cap Pro LLC, funded a special purpose account on behalf of MEDX HOLDINGS, INC. in the amount of \$ 15,000.00 with the sole purpose of providing working capital to restructure the operations, move the state of domicile from Colorado to Wyoming, and to establish corporate operations in order to implement the current strategic business plan. This note carries a statutory interest rate, is unsecured and is due on demand. As of 12/31/2015 the un-used amount in the SPE account was \$ 1709.25. The board of directors authorized that the claim of \$ 1709.25 towards Medx Holdings Inc. be released and the account be returned to its beneficial owner, Small Cap Pro LLC. Small Cap Pro LLC is wholly owned by the principle shareholder of MedX Holdings, Inc.

**NOTE 5 – CAPITAL STOCK**

As of December 31, 2016 the Company has:

|                                  |                               |
|----------------------------------|-------------------------------|
| Authorized Common Shares         | 100,000,000 Par Value \$0.001 |
| Authorized Blank Check Preferred | 97,000,000 Par Value \$0.001  |
| Issued Series "A" Preferred      | 3,000,000                     |
| Issued and outstanding: COMMON   | 28,069,016                    |

**NOTE 6 – SUBSEQUENT EVENTS**

The Company has evaluated subsequent events from the balance sheet date through the date the financial statements were available to be issued and has determined the following significant events that need to be disclosed:

- i. As of January 2, 2017, the Warehouse/Office at 750 Lakeside Drive, Suite A Mobile Alabama 36693 was returned to the owner and the 5-Year lease was "Forgiven".
- ii. As of January 10, 2017, the Sales Office at 1500 Cypress Creek Rd, Fort Lauderdale Florida 33309. This lease is still pending agreed settlement of \$3,180.00.

## **Item 6: Nature of the Issuer's Business**

MEDH was sold during the fiscal year of 2016 to Kathleen A. Robertson. Donald Schellpfeffer MD/PHD resigned as President, Secretary and Chief Executive Officer. MedX is a developmental business. In 2016 MedX acquired MedX Pharmaceuticals which is licensed as a Mfr./Wholesaler/Repackager of Pharmaceuticals Drugs in the state of Alabama.

MedX Pharmaceuticals secured a relationship with Amneal Pharmaceuticals who is one of the largest FDA approved manufactures. Our focused product during 2016 was a 5% Topical Lidocaine Ointment which is an RX Product.

The Company's fiscal year end is December 31<sup>st</sup>. The Company has not been involved in any bankruptcy, receivership, or any similar proceeding.

The Company is not currently subject to any legal action or in default of any debt covenants.

### **A. The form of organization of the Issuer:**

MedX Holdings, Inc. is a Wyoming Corporation

MedX Pharmaceuticals, Inc. is a Alabama Corporation and is a "Arm's Length" Wholly-owned Subsidiary of MedX Holdings, Inc.

### **B. This Year that the Issuer (or predecessor was organized):**

The Company was incorporated on September 5, 2006 as Disaboo, Inc. under the laws of the state of Colorado.

## **Item 7: Describe the Issuer's Facilities**

### **Corporate Office: MedX Holdings, Inc.**

1621 Central Avenue  
Cheyenne, WY 82001

### **Corporate Office: MedX Pharmaceuticals, Inc.**

750 Lakeside Drive, Suite A, Mobile Alabama

### **Sales Office: MedX Pharmaceuticals, Inc.**

1500 Cypress Creek Road, Fort Lauderdale, FL 33304

**Item 8: Officers, Directors and Control Persons:**

A. Kathleen Robertson servers of Officer, Director and Control Person.

B. Legal/Disciplinary History:

None

C. Beneficial Owner

Kathleen Robertson  
1621 Central Avenue  
Cheyenne, Wyoming 92001  
Percentage: Greater than 76%

**Item 9: Third Party Providers**

Legal Counsel:

Lorin A. Rosen, Esq.  
Managing Attorney  
Lar Law Firm  
6 Butler Court  
Centereach, NY 11720

Irick CPA  
Box 732  
Counselor, NM 87018

**Subsequent Events:**

January 2017 – MedX Pharmaceutical officially went out of business due price competition and regulatory laws. Thus, MedX Pharmaceuticals was forced to vacate the office in Mobile Alabama and was released from their 5-Year lease with no penalty or liability. MedX Pharmaceuticals also vacated the sales office in Fort Lauderdale, FL with a negotiated settlement of \$3,200. This payment is still pending.



**Item 10 : Issuer Certification:**

I Kathleen Robertson certify that:

1. I have reviewed this Annual Report
2. Based on my knowledge, this disclosure statement does not contain any untrue statements of material fact or omit to state a material fact necessary to make the statements made. In light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the period presented in this disclosure.

/s/ Kathleen Robertson, CEO

Kathleen Robertson, CEO